ARL3 and breast cancer: Prognostic meta‐analysis using GEPIA and KM plotter demonstrated that elevated ARL3 expression correlates with significantly shorter overall survival in pan‐breast cancer cohorts (Figure 1G,H), with particularly adverse outcomes in luminal breast cancer patients (Figure S1G, Supporting Information).